Patents by Inventor Lars G. Ostberg

Lars G. Ostberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human monoclonal antibodies to cytomegalovirus
    Patent number: 5750106
    Abstract: The present invention is directed to the human monoclonal antibody designated SDZ MSL 109 produced by the hybridoma cell line designated EV 2-7 having NCACC Accession No. 85 100 803. The human monoclonal antibody is specific for cytomegalovirus (CMV) and is useful as a therapeutic agent for treating CMV infections.
    Type: Grant
    Filed: June 25, 1993
    Date of Patent: May 12, 1998
    Assignee: Novartis AG
    Inventor: Lars G. Ostberg
  • Treatment of patients infected with hepatitis B virus with a human monoclonal antibody
    Patent number: 5648077
    Abstract: Monoclonal antibodies effective for the diagnosis and treatment of hepatitis B have been prepared from a cell line obtained by fusing a xenogeneic hybridoma designated SPAZ 4 with blood cells of a patient immunized with hepatitis B vaccine. The chimeric human monoclonal antibody, PE1-1, (ATCC HB 9234), is used in a method of treating patients infected with hepatitis B virus.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 15, 1997
    Assignee: Sandoz Ltd.
    Inventor: Lars G. Ostberg
  • Monoclonal antibody to herpes simplex virus and cell line producing same
    Patent number: 5646041
    Abstract: Human Monoclonal antibodies effective for the diagnosis and treatment of Herpes Simplex Virus 1 and 2 have been prepared from a cell line obtained by fusing a xenogeneic hybridoma designated SPAZ 4 with spleen cells of a patient immune to Herpes Simplex Virus.
    Type: Grant
    Filed: September 13, 1994
    Date of Patent: July 8, 1997
    Inventors: Elisabeth Harfeldt, Philip Lake, Barbara Nottage, Lars G. Ostberg
  • Production of human monoclonal antibodies specific for hepatitis B surface antigen
    Patent number: 5565354
    Abstract: Monoclonal antibodies effective for the diagnosis and treatment of diseases caused by infection with hepatitis B have been prepared from a cell line obtained by fusing a xenogeneic hybridoma designated SPAZ 4 with blood cells of a patient immunized with hepatitis B vaccine. The invention also provides cocktails of the above monoclonal antibodies specific for different epitopes of hepatitis B surface antigen.
    Type: Grant
    Filed: June 14, 1994
    Date of Patent: October 15, 1996
    Assignee: Sandoz Ltd.
    Inventor: Lars G. Ostberg